# Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

> **NCT06802757** · PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 72 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Posaconazole
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Anthracycline
- **DRUG:** Cyclophosphamide
- **DRUG:** PD-1 inhibitors

## Key facts

- **NCT ID:** NCT06802757
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-02-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06802757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06802757, "Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06802757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*